← Russell 3000 cross-section

ADPT Adaptive Biotechnologies Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$4.3bn
Revenue TTM
$308m
Net income TTM
$-64m
Free cash flow
$-24m
Composite score
52.1
Sector rank
#1183

Valuation

P / E
EV / EBITDA
EV / sales
12.7
FCF yield
-0.56%
Earnings yield vs 10-yr
-6.23pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-20.7%
EBITDA margin
-6.9%
ROE
-44.7%
ROIC
Revenue growth
50.1%

Insider activity, last 90 days

Net open-market
$-50.57m
Buyers
0
Sellers
9

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered. The following table presents our disaggregated revenue for the periods presented (in thousands): (1) On August 13, 2025, the Genentech Agreement was terminated, with termination effective February 9, 2026. …Adaptive Biotechnologies Corp, 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →